Informationen:
Fehler:
ID
39315
Beschreibung
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01303679
Link
https://clinicaltrials.gov/show/NCT01303679
Stichworte
Versionen (1)
- 18.12.19 18.12.19 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
18. Dezember 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility First Line Metastatic Breast Cancer NCT01303679
Eligibility First Line Metastatic Breast Cancer NCT01303679
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility First Line Metastatic Breast Cancer NCT01303679
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Age
Item
age > 18 ans.
boolean
C0001779 (UMLS CUI [1])
Secondary malignant neoplasm of female breast | Locally advanced breast cancer
Item
metastatic breast cancer or locally advanced
boolean
C0346993 (UMLS CUI [1])
C3495949 (UMLS CUI [2])
C3495949 (UMLS CUI [2])
Estrogen receptor positive | HER2 Negative
Item
re+, her2-
boolean
C0279754 (UMLS CUI [1])
C2348908 (UMLS CUI [2])
C2348908 (UMLS CUI [2])
Chemotherapeutics regimen first line of treatment | Paclitaxel | bevacizumab
Item
patient receiving paclitaxel-bevacizumab first line chemotherapy
boolean
C2045825 (UMLS CUI [1])
C0144576 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
C0144576 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
Prior Adjuvant Therapy | exemestane | Prior Therapy metastatic
Item
previous treatment by exemestane (both in adjuvant or metastatic treatment).
boolean
C1514456 (UMLS CUI [1])
C0851344 (UMLS CUI [2])
C1514463 (UMLS CUI [3,1])
C1522484 (UMLS CUI [3,2])
C0851344 (UMLS CUI [2])
C1514463 (UMLS CUI [3,1])
C1522484 (UMLS CUI [3,2])
Cemotherapeutics regimen first line of treatment | Except Paclitaxel | Except Bevacizumab
Item
1st line of chemotherapy different thaan paclitaxel-bevacizumab.
boolean
C2045825 (UMLS CUI [1])
C0332300 (UMLS CUI [2,1])
C0144576 (UMLS CUI [2,2])
C0332300 (UMLS CUI [3,1])
C0796392 (UMLS CUI [3,2])
C0332300 (UMLS CUI [2,1])
C0144576 (UMLS CUI [2,2])
C0332300 (UMLS CUI [3,1])
C0796392 (UMLS CUI [3,2])
Prior Therapy | Paclitaxel | bevacizumab
Item
treatment by paclitaxel-bevacizumab > 18 weeks.
boolean
C1514463 (UMLS CUI [1])
C0144576 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
C0144576 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
HER2 Positive | Estrogen receptor negative
Item
her2 positifs et/ou récepteurs aux oestrogènes négatifs.
boolean
C2348909 (UMLS CUI [1])
C0279756 (UMLS CUI [2])
C0279756 (UMLS CUI [2])
Thrombosis Event Previous
Item
previous thrombosis event within the 6 months before inclusion .
boolean
C0040053 (UMLS CUI [1,1])
C0441471 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
C0441471 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
Prior surgery
Item
previous significant surgery within the 28 days before treatment start
boolean
C0455610 (UMLS CUI [1])
Blood Coagulation Disorder Previous
Item
previuous coagulopathy.
boolean
C0005779 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,2])